What are the side effects and effectiveness of letrozole (aromatase inhibitor) when used for ovulation induction in IVF cycles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Letrozole for IVF: Effectiveness and Side Effects

Letrozole demonstrates superior live birth rates compared to clomiphene citrate for ovulation induction in women with PCOS (27-35% vs 20%), with comparable safety profiles and no increased risk of ovarian hyperstimulation syndrome. 1, 2

Effectiveness for IVF and Ovulation Induction

Live Birth and Pregnancy Outcomes

Letrozole shows marked superiority over traditional first-line agents:

  • Live birth rate: 1.72 times higher than clomiphene citrate (translating to 27-35% vs 20% baseline rate; NNTB = 10) 2
  • Clinical pregnancy rate: 1.69 times higher than clomiphene (32-39% vs 24%; NNTB = 10) 2
  • Cumulative clinical pregnancy rate: 38% vs 34% when including fresh and frozen embryo transfers 3

The Endocrine Society guidelines now recognize letrozole as comparable to clomiphene citrate for first-line treatment of anovulatory infertility in PCOS, noting that a large NIH-sponsored multicenter trial (n=750) demonstrated marked superiority in live birth rates 1.

Specific IVF Applications

For poor responders: Letrozole combined with high-dose FSH/hMG increases:

  • Number of oocytes retrieved (6.1 vs 4.3) 4
  • Implantation rate (25% vs 9.4%) 4
  • Intraovarian androgen concentrations (testosterone 80.3 vs 43.8 pg/mL) 4

For normal responders: Recent high-quality RCT data shows letrozole co-treatment during ovarian stimulation does NOT significantly impact:

  • Follicle recruitment or oocyte numbers (8.0 vs 7.9 oocytes) 3
  • Embryo quality or utilization rates 3
  • Live birth rates per transfer (28% vs 37%, not statistically significant) 3

Important caveat: In the ICSI subgroup, letrozole reduced MII oocyte rates (75% vs 88%), though this did not translate to worse pregnancy outcomes 3.

Side Effects and Safety Profile

Ovarian Hyperstimulation Syndrome (OHSS)

High-certainty evidence shows identical OHSS rates between letrozole and clomiphene (0.5% in both groups) 2. This is a critical safety advantage over gonadotropins alone.

For OHSS prevention in high-risk patients: Letrozole administered during the luteal phase dramatically reduces estradiol levels but does NOT reduce severe OHSS rates (16% vs 19%, not significant) 5. The Endocrine Society suggests metformin as the preferred adjuvant for OHSS prevention in IVF cycles 1.

Pregnancy-Related Outcomes

  • Miscarriage rate: No difference compared to clomiphene (24% vs 25%) 2
  • Multiple pregnancy rate: No difference (1.6% vs 2.2%) 2
  • Teratogenicity concerns: Initial concerns about teratogenicity have been largely dispelled by reassuring trial data 1

Common Side Effects

The FDA label indicates letrozole is generally well-tolerated. Based on its mechanism as an aromatase inhibitor 6:

  • Suppresses estradiol, estrone, and estrone sulfate by 75-95% within 2-3 days 6
  • Does NOT impair adrenal steroidogenesis (no effect on cortisol, aldosterone, ACTH) 6
  • Does NOT require glucocorticoid or mineralocorticoid supplementation 6
  • Does NOT affect thyroid function 6

No serious maternal or fetal adverse effects have been reported in reproductive medicine applications 1.

Clinical Algorithm for Use

When to Use Letrozole in IVF:

  1. First-line for PCOS ovulation induction (preferred over clomiphene based on superior live birth rates) 1, 2

  2. Poor ovarian responders: Add letrozole 2.5 mg to FSH/hMG antagonist protocol during first 5 days of stimulation 4, 7

  3. Fertility preservation in estrogen-sensitive cancers: Letrozole reduces supraphysiologic estradiol exposure 8, 9

  4. NOT recommended for: Normal responders seeking improved oocyte yield or embryo quality (no benefit demonstrated) 3

When NOT to Use:

  • Routine luteal phase administration for OHSS prevention (ineffective despite lowering estradiol) 5
  • Routine use in normal responders (no improvement in outcomes) 3

Dosing:

  • Standard dose: 2.5 mg daily for 5 days during early follicular phase 4
  • For luteal phase: 5 mg daily for 5 consecutive days (though efficacy for OHSS prevention is questionable) 5

Key Clinical Pitfalls

  1. Don't expect OHSS prevention from luteal letrozole: Despite dramatic estradiol reduction, severe OHSS rates remain unchanged 5

  2. Monitor ICSI cycles more carefully: Reduced MII rates observed in one trial, though clinical significance unclear 3

  3. Letrozole vs laparoscopic ovarian drilling: Very low-certainty evidence suggests possible superiority (OR 2.07), but data insufficient for firm recommendations 2

  4. Cost-effectiveness: Letrozole offers significant cost advantages over gonadotropins while maintaining comparable or superior outcomes 8

References

5
Research

[Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2013

7
Research

Aromatase inhibitors in stimulated IVF cycles.

Reproductive biology and endocrinology : RB&E, 2011

Related Questions

In a patient undergoing letrozole ovulation induction, on cycle day 23 with two corpus lutea, no intra‑uterine gestational sac, and free fluid in the pouch of Douglas, could these findings represent a normal post‑ovulatory condition?
How long after stopping letrozole (Femara) should a woman with a history of induced ovulation wait to assess if her hypothalamic function has recovered and spontaneous ovulation can occur?
How long should letrozole be continued?
How to manage a thin endometrium in patients taking Letrozole (Femara) for ovulation induction?
Can letrozole be taken concurrently with a vitamin B complex supplement?
Should a patient with chronic heart failure and a left ventricular ejection fraction of 15% receive the annual influenza vaccine?
What is the recommended antibiotic therapy for Pseudomonas otitis externa in a 23-year-old female?
In a 68‑year‑old man undergoing transurethral resection of the prostate (TURP), is recovery typically as simple as an overnight hospital stay and return to normal activities within two weeks?
Can a patient with a childhood penicillin allergy safely take Augmentin (amoxicillin/clavulanate)?
What is the first medication to initiate in an 18‑year‑old female adolescent with severe depression and passive suicidal thoughts but no plan or homicidal ideation?
What level of sterility is required for incision and drainage of an abscess?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.